Active Ingredient: Icatibant
Icatibant is indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults, adolescents, with C1-esterase-inhibitor deficiency.
For this indication, competent medicine agencies globally authorize below treatments:
Subcutaneous
30 - 30 mg
From 30 To 30 mg once every day
The recommended dose for adults is a single subcutaneous injection of icatibant 30 mg.
In the majority of cases a single injection of icatibant is sufficient to treat an attack. In case of insufficient relief or recurrence of symptoms, a second injection of icatibant can be administered after 6 hours. If the second injection produces insufficient relief or a recurrence of symptoms is observed, a third injection of icatibant can be administered after a further 6 hours. No more than 3 injections of icatibant should be administered in a 24 hour period.
In the clinical trials, not more than 8 injections of icatibant per month have been administered.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
